Asset sale Completed

Cosette Pharmaceuticals acquisition of Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup)

US$35m consideration

Announced 8 Apr 2026

Advisers

Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup)

Target

Financial adviser
Legal adviser

Cosette Pharmaceuticals

Acquirer

Not disclosed

Target
Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup)
Acquirer
Cosette Pharmaceuticals
Seller
Assertio Holdings
Target based in
United States
Buyer based in
United States
Seller based in
United States
Completed
8 Apr 2026
Sector
Pharma

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.